GRI Bio (NASDAQ:GRI) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of GRI Bio (NASDAQ:GRI) in a research report released on Monday morning,Benzinga reports. They currently have a $10.00 target price on the stock.

GRI Bio Price Performance

Shares of GRI stock opened at $1.51 on Monday. The business has a 50-day moving average of $5.85 and a 200 day moving average of $9.93. GRI Bio has a 1-year low of $1.10 and a 1-year high of $130.39. The stock has a market capitalization of $792,750.00, a PE ratio of -0.13 and a beta of -1.72.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GRI Bio stock. Geode Capital Management LLC raised its position in GRI Bio, Inc. (NASDAQ:GRI) by 543.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,182 shares of the company’s stock after acquiring an additional 64,335 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of GRI Bio worth $63,000 at the end of the most recent quarter. Institutional investors own 33.95% of the company’s stock.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.